Multiple Endocrine Neoplasia Medical Services in China

Multiple Endocrine Neoplasia (MEN) is a group of rare, inherited autosomal dominant disorders characterized by the development of tumors—often benign but sometimes malignant—in two or more endocrine glands. The three main clinical subtypes are MEN1, MEN2A, and MEN2B, each defined by distinct genetic mutations, tumor spectra, and natural histories. MEN1 is caused by inactivating mutations in the *MEN1* tumor suppressor gene on chromosome 11q13, leading to hyperplasia and neoplasia primarily in the parathyroid glands (90–95% prevalence), anterior pituitary (30–40%), and pancreaticoduodenal neuroendocrine tissues (30–80%, including gastrinomas, insulinomas, and non-functioning tumors). MEN2 syndromes arise from gain-of-function mutations in the *RET* proto-oncogene on chromosome 10q11.2; MEN2A features medullary thyroid carcinoma (MTC, nearly 100% penetrance), pheochromocytoma (50%), and primary hyperparathyroidism (20–30%), while MEN2B adds mucosal neuromas, marfanoid habitus, and aggressive MTC with early onset. Pathogenesis centers on dysregulated cell proliferation, apoptosis evasion, and hormone hypersecretion due to germline mutation-driven endocrine cell transformation. Epidemiologically, MEN1 affects approximately 1 in 30,000 individuals, with no gender predilection; MEN2 occurs in roughly 1 in 35,000–50,000. Penetrance is high (>95% for key components by age 50), and de novo mutations account for <5% of cases. Key risk factors include a confirmed pathogenic germline variant and a first-degree relative with MEN—making genetic counseling and predictive testing critical for at-risk family members. Diagnosis relies on clinical criteria, biochemical screening (e.g., serum calcium, PTH, prolactin, gastrin, calcitonin, metanephrines), imaging (MRI, CT, Ga-68 DOTATATE PET/CT), and confirmatory germline genetic testing. Untreated or suboptimally managed MEN significantly impairs quality of life: recurrent hypercalcemia causes fatigue, nephrolithiasis, and cognitive fog; hormone-secreting tumors provoke debilitating symptoms (e.g., Zollinger–Ellison syndrome diarrhea/ulcers, insulinoma-induced neuroglycopenia, pheochromocytoma-related hypertension crises); surgical interventions carry risks of hypoparathyroidism or adrenal insufficiency; and lifelong surveillance generates psychological burden, financial strain, and occupational limitations. Early diagnosis, risk-stratified prophylactic surgery (especially thyroidectomy in *RET* carriers), targeted medical therapies (e.g., everolimus for progressive pancreatic NETs, vandetanib for advanced MTC), and multidisciplinary care—including endocrinology, endocrine surgery, nuclear medicine, genetics, and oncology—are essential to mitigate morbidity, prevent metastatic disease, and preserve long-term function and well-being.

Multiple Endocrine Neoplasia (MEN) syndromes are rare, autosomal dominant hereditary disorders characterized by the development of tumors—often benign or malignant—in two or more endocrine glands. The three principal subtypes are MEN1, MEN2A, and MEN2B; each arises from distinct germline mutations and exhibits unique phenotypic expression. The primary cause of all MEN syndromes is pathogenic variants in specific tumor suppressor or proto-oncogenes: MEN1 results from loss-of-function mutations in the *MEN1* gene on chromosome 11q13, encoding the nuclear protein menin, which regulates transcription, genome stability, and epigenetic modification. MEN2A and MEN2B are caused by gain-of-function missense mutations in the *RET* proto-oncogene on chromosome 10q11.2, leading to constitutive activation of the RET tyrosine kinase receptor and uncontrolled cell proliferation in neural crest–derived tissues—including parathyroid, thyroid C-cells, and adrenal medulla. These genetic alterations are necessary and sufficient for disease initiation; no acquired somatic mutation alone accounts for the multisystem endocrine neoplasia pattern observed in MEN. While the genetic defect is the fundamental cause, disease penetrance and expressivity vary significantly—even among family members sharing identical mutations—suggesting modulation by genetic modifiers, epigenetic regulation, and stochastic cellular events.

Triggers for clinical manifestation are not environmental but rather developmental and hormonal. For example, hypercalcemia in MEN1-related primary hyperparathyroidism typically emerges in the third decade, often precipitated by physiological stressors such as pregnancy, lactation, or immobilization that unmask latent parathyroid hyperfunction. In MEN2, elevated calcitonin levels may be acutely stimulated by pentagastrin or calcium infusion during provocative testing—though these are diagnostic tools, not true disease triggers. Similarly, catecholamine surges in pheochromocytoma (common to MEN2A/2B and occasionally MEN1) can be provoked by anesthesia, surgery, or sympathomimetic agents, potentially triggering hypertensive crises—but again, these unmask rather than initiate neoplasia.

Established risk factors are overwhelmingly genetic. A first-degree relative with confirmed MEN confers a 50% lifetime risk of inheriting the pathogenic variant. Age is a strong epidemiological risk factor: by age 50, >95% of *MEN1* carriers exhibit at least one endocrine tumor; similarly, >90% of *RET* mutation carriers develop medullary thyroid carcinoma (MTC) by age 70 without prophylactic thyroidectomy. Sex does not confer differential risk, though some studies suggest slightly earlier MTC onset in males with certain *RET* codon 634 mutations. Prior radiation exposure is not associated with MEN syndromes—unlike sporadic thyroid cancer—and thus is not considered a relevant environmental risk factor. No robust evidence links diet, toxins, smoking, or occupational exposures to MEN incidence or progression. However, comorbid conditions may influence morbidity: for instance, chronic proton pump inhibitor use in MEN1-associated gastric enterochromaffin-like (ECL) cell hyperplasia may theoretically promote progression to neuroendocrine carcinoma, though causality remains unproven. Likewise, uncontrolled diabetes or obesity may exacerbate complications of MEN1-related pancreatic neuroendocrine tumors (e.g., insulinoma-induced hypoglycemia), but they do not increase tumor development risk.

Environmental factors play no etiologic role in MEN pathogenesis. Unlike many cancers, MEN syndromes are not associated with ionizing radiation, chemical carcinogens, infectious agents, or lifestyle variables. The absence of environmental contribution underscores the purely genetic basis of these disorders. Nevertheless, environmental context influences surveillance adherence and intervention timing: access to genetic counseling, high-volume endocrine surgical centers, and molecular testing infrastructure significantly affects outcomes. Delayed diagnosis due to limited healthcare access or lack of cascade genetic testing represents a modifiable systemic risk factor—not biological, but clinically consequential.

In summary, MEN syndromes are monogenic, inherited conditions driven exclusively by germline *MEN1* or *RET* mutations. Triggers are largely physiological or iatrogenic unmasking events rather than causal agents. Risk stratification relies on genotype–phenotype correlations (e.g., *RET* codon-specific MTC aggressiveness), age, and family history—not environmental exposure. Prophylactic management—including risk-reducing thyroidectomy in *RET* carriers—is guided entirely by molecular genetics, affirming that prevention in MEN is fundamentally genomic medicine.

Multiple Endocrine Neoplasia (MEN) comprises a group of rare, autosomal dominant hereditary syndromes characterized by the development of tumors—often benign but sometimes malignant—in two or more endocrine glands. The three principal subtypes are MEN1, MEN2A, and MEN2B, each defined by distinct genetic mutations (MEN1 gene on chromosome 11q13 for MEN1; RET proto-oncogene gain-of-function mutations on chromosome 10q11.2 for MEN2A and MEN2B), characteristic tumor spectra, and differing natural histories. Early symptoms are frequently subtle, nonspecific, and attributable to hormonal hypersecretion or mass effect from small, asymptomatic tumors—making diagnosis challenging without high clinical suspicion and genetic awareness.

Early symptoms vary significantly by subtype and affected gland. In MEN1, early manifestations often reflect primary hyperparathyroidism: fatigue, mild depression, constipation, polyuria, and nonspecific bone or joint aches due to mild hypercalcemia—sometimes detected incidentally on routine serum calcium screening. Gastrinomas may present with recurrent epigastric discomfort, heartburn, or iron-deficiency anemia before overt peptic ulcer disease develops. Insulinomas may cause fasting hypoglycemia with neuroglycopenic symptoms (e.g., confusion, diaphoresis, tremor, or seizures) in young adults—often misattributed to anxiety or epilepsy. In MEN2A, the earliest detectable abnormality is often elevated basal or stimulated calcitonin, preceding medullary thyroid carcinoma (MTC) symptoms by years; however, some patients report vague neck fullness, persistent hoarseness, or intermittent diarrhea (due to calcitonin or other peptide co-secretion) prior to palpable thyroid nodule detection. In MEN2B, mucosal neuromas may appear in infancy or early childhood as painless, fleshy, bluish nodules on lips, tongue, and eyelids—often prompting initial pediatric evaluation—but are frequently overlooked. Marfanoid habitus and gastrointestinal dysmotility (e.g., chronic constipation or pseudo-obstruction) may also manifest early in childhood.

Typical symptoms emerge as tumors enlarge or hormone excess becomes clinically significant. In MEN1, classic triad includes primary hyperparathyroidism (present in >90% by age 50), enteropancreatic neuroendocrine tumors (e.g., gastrinoma causing Zollinger–Ellison syndrome with severe, refractory peptic ulcer disease, gastroesophageal reflux, and diarrhea; insulinoma causing Whipple’s triad; glucagonoma with necrolytic migratory erythema, diabetes, and weight loss), and pituitary adenomas (prolactinoma causing amenorrhea-galactorrhea or infertility; somatotropinoma causing acromegaly with coarse facial features, jaw enlargement, and arthropathy; corticotropinoma causing Cushing’s disease). In MEN2A, typical presentation involves MTC (palpable thyroid nodule, cervical lymphadenopathy, dysphagia, or stridor), pheochromocytoma (episodic headache, palpitations, diaphoresis, pallor, and hypertension—often paroxysmal and resistant to standard antihypertensives), and primary hyperparathyroidism (similar to MEN1 but less penetrant, occurring in ~20–30%). MEN2B presents with aggressive, early-onset MTC (often diagnosed <10 years old), pheochromocytoma (similar to MEN2A), and distinctive physical features: mucosal neuromas, thickened corneal nerves, intestinal ganglioneuromatosis (causing megacolon or chronic constipation), and marfanoid body habitus without lens dislocation or cardiovascular fragility.

Accompanying symptoms reflect multisystem involvement and paraneoplastic phenomena. Patients may exhibit dermatologic findings (e.g., angiofibromas, collagenomas, or café-au-lait spots in MEN1; mucosal neuromas in MEN2B), skeletal abnormalities (osteoporosis secondary to chronic hypercalcemia or acromegaly), ocular signs (corneal nerve thickening on slit-lamp exam in MEN2B), and neuropsychiatric manifestations (depression, cognitive slowing, or anxiety linked to chronic hormonal dysregulation or tumor burden). Gastrointestinal motility disorders—including gastroparesis, chronic diarrhea, or constipation—are common across subtypes due to autonomic neuropathy, hormonal effects (e.g., VIPoma-induced watery diarrhea), or ganglioneuromatosis.

Complications arise from both hormonal excess and tumor progression. Life-threatening complications include MTC metastasis (to regional lymph nodes, liver, lungs, or bone), catecholamine crisis precipitated by pheochromocytoma (especially perioperatively), gastric perforation or hemorrhage from gastrinoma-related ulcers, hypoglycemic coma from insulinoma, and adrenal insufficiency following bilateral adrenalectomy for pheochromocytoma. Long-term hypercalcemia leads to nephrolithiasis, nephrocalcinosis, and renal failure. Pituitary macroadenomas may cause visual field defects (bitemporal hemianopsia) or panhypopituitarism. Metastatic neuroendocrine tumors confer poor prognosis, particularly in MEN1-associated pancreatic NETs with high Ki-67 index or liver metastases.

Diagnosis relies on integrated clinical assessment, biochemical testing, imaging, and germline genetic testing. Biochemical screening includes serum calcium, PTH, gastrin, fasting glucose/insulin/C-peptide, prolactin, IGF-1, cortisol (with dexamethasone suppression), plasma free metanephrines, and calcitonin (basal and pentagastrin- or calcium-stimulated). Imaging modalities include neck ultrasound and contrast-enhanced CT/MRI for thyroid/parathyroid/pancreatic/pituitary evaluation; 68Ga-DOTATATE PET/CT for well-differentiated NETs; and 18F-FDG PET/CT for aggressive or dedifferentiated lesions. Genetic testing for MEN1 or RET mutations is confirmatory and essential for at-risk family members; predictive testing guides prophylactic thyroidectomy timing in RET carriers (e.g., within first year of life for MEN2B, by age 5 for high-risk RET codon 634 mutations).

Differential diagnosis must exclude sporadic endocrine tumors, autoimmune polyglandular syndromes (APS-1 and APS-2), VHL syndrome (which features pheochromocytoma, pancreatic NETs, and hemangioblastomas but lacks parathyroid or pituitary involvement), neurofibromatosis type 1 (causing pheochromocytoma and duodenal somatostatinomas but not hyperparathyroidism), and Carney complex (characterized by spotty skin pigmentation, cardiac myxomas, and acromegaly but no MTC or gastrinoma). Distinguishing MEN2B from Marfan syndrome or Ehlers–Danlos syndrome requires careful phenotyping and genetic analysis, as mucosal neuromas and corneal nerve thickening are pathognomonic. Accurate classification is critical: misdiagnosis delays life-saving prophylactic surgery in MEN2 and inappropriate surveillance in non-MEN conditions.

Multiple Endocrine Neoplasia (MEN) syndromes are rare, autosomal dominant hereditary disorders characterized by the development of tumors in two or more endocrine glands. The three principal subtypes—MEN1, MEN2A, and MEN2B—differ in genetic basis, tumor spectrum, and clinical behavior. MEN1 is caused by germline mutations in the *MEN1* tumor suppressor gene on chromosome 11q13 and commonly involves parathyroid adenomas (≥90%), pancreatic neuroendocrine tumors (pNETs; 30–80%), and pituitary adenomas (15–50%). MEN2A and MEN2B result from gain-of-function mutations in the *RET* proto-oncogene (chromosome 10q11.2); MEN2A features medullary thyroid carcinoma (MTC; nearly 100% penetrance), pheochromocytoma (50%), and primary hyperparathyroidism (20–30%), whereas MEN2B presents with aggressive MTC (earlier onset), pheochromocytoma, mucosal neuromas, and marfanoid habitus—but rarely parathyroid disease. Management requires lifelong, multidisciplinary surveillance and individualized intervention guided by genotype-phenotype correlations, tumor burden, functional status, and growth kinetics.

Conservative treatment forms the cornerstone of long-term care and emphasizes vigilant monitoring rather than immediate intervention. For asymptomatic or biochemically stable patients—particularly those with small, nonfunctional pNETs (<2 cm), microprolactinomas, or mild primary hyperparathyroidism—active surveillance is recommended. This includes annual serum calcium, intact PTH, fasting gastrin, insulin, glucagon, chromogranin A, plasma metanephrines, and calcitonin; biannual neck ultrasound; triennial abdominal MRI or contrast-enhanced CT for pNET screening; and periodic pituitary MRI and visual field testing. Surveillance intervals are intensified for high-risk *RET* codon mutations (e.g., M918T in MEN2B) or documented tumor progression. Lifestyle counseling—including calcium/vitamin D optimization, avoidance of dopamine antagonists in prolactinoma carriers, and strict blood pressure control in pheochromocytoma-prone individuals—is integral to conservative strategy.

Pharmacotherapy serves adjunctive or palliative roles but is rarely curative. Somatostatin analogues (octreotide LAR, lanreotide) are first-line for symptomatic, well-differentiated pNETs (e.g., insulinoma, gastrinoma) to control hormonal hypersecretion and slow tumor growth; they reduce diarrhea, flushing, and hypoglycemia while demonstrating antiproliferative effects in NETs expressing SSTR2/5. Tyrosine kinase inhibitors (vandetanib, cabozantinib) are FDA-approved for progressive, metastatic MTC refractory to surgery, improving progression-free survival by targeting RET, VEGFR2, and EGFR pathways. For prolactinomas, dopamine agonists (cabergoline, bromocriptine) normalize prolactin and shrink tumor volume in >80% of cases. Alpha- and beta-adrenergic blockade (phenoxybenzamine followed by propranolol or atenolol) is mandatory preoperatively in pheochromocytoma to prevent intraoperative catecholamine crisis. Calcimimetics (cinacalcet) may temporize hypercalcemia in MEN1-related hyperparathyroidism when surgery is contraindicated, though they do not prevent parathyroid hyperplasia progression.

Surgical treatment remains the only potentially curative modality and is dictated by syndrome subtype and tumor biology. Prophylactic total thyroidectomy is indicated in all *RET* mutation carriers: timing is risk-stratified—by age 5 years for highest-risk (MEN2B, codon M918T), by age 5–10 years for high-risk (MEN2A, codons C634, A883F), and by age 10–20 years for moderate-risk (codons G533C, V804M/L). Central lymph node dissection is performed concurrently if calcitonin elevation or nodal involvement is evident. For pheochromocytoma, laparoscopic adrenalectomy is standard; bilateral disease warrants cortical-sparing resection when feasible to avoid lifelong glucocorticoid dependence. Parathyroidectomy in MEN1 typically involves subtotal (3.5-gland) or total parathyroidectomy with autotransplantation, given the near-universal multiglandular hyperplasia. Pancreatic surgery is selective: enucleation for small, benign insulinomas; distal pancreatectomy ± spleen preservation for larger or multifocal pNETs; and Whipple procedure only for duodenal gastrinomas with local invasion. Pituitary surgery (transsphenoidal resection) is indicated for acromegaly, Cushing disease, or mass effect—not for incidental microadenomas.

Treatment advantages in China include centralized expertise at national referral centers (e.g., Peking Union Medical College Hospital, Shanghai Ruijin Hospital), where integrated endocrine-oncology-genetics teams deliver standardized, protocol-driven care aligned with international guidelines (ATA, ENETS, NANETS). China’s robust genomic infrastructure enables rapid, cost-effective *RET* and *MEN1* sequencing (turnaround <10 days), facilitating early diagnosis in probands and cascade testing in at-risk relatives. Minimally invasive surgical techniques—including robotic-assisted thyroidectomy and fluorescence-guided parathyroid mapping—are widely adopted in tier-1 hospitals, reducing complication rates (e.g., recurrent laryngeal nerve injury <1%, permanent hypoparathyroidism <5%). Moreover, China’s National Reimbursement Drug List includes vandetanib, octreotide LAR, and cabergoline, significantly improving accessibility compared to regional counterparts. Clinical trial participation is expanding, with Chinese sites actively enrolling in global phase III studies of novel RET inhibitors (e.g., selpercatinib, pralsetinib) and peptide receptor radionuclide therapy (¹⁷⁷Lu-DOTATATE) for advanced NETs.

Recovery advice emphasizes structured, lifelong follow-up. Patients must adhere strictly to scheduled biochemical and imaging surveillance—even after successful surgery—as recurrence or new primary tumors remain likely. Post-thyroidectomy, levothyroxine replacement is titrated to suppress TSH without inducing atrial fibrillation or osteoporosis; calcitonin and CEA monitoring continues every 6 months indefinitely. After parathyroid surgery, serum calcium and PTH require weekly checks initially, then quarterly, with oral calcium and calcitriol supplementation as needed until gland function stabilizes. All MEN patients should wear medical alert identification and carry emergency hydrocortisone kits if adrenalectomized. Genetic counseling is mandatory before family planning; prenatal testing and preimplantation genetic diagnosis are available. Psychosocial support—including peer networks facilitated by the Chinese Endocrine Society—is encouraged to mitigate anxiety related to chronic cancer risk. Finally, patients should avoid iodinated contrast media unless absolutely necessary (due to interference with radioactive iodine scans in MTC follow-up) and consult their endocrinologist before initiating any new medication, especially NSAIDs (gastrinoma risk) or calcium channel blockers (pheochromocytoma interaction). With coordinated, proactive management, 10-year survival exceeds 90% for MEN2A and 75% for MEN1—underscoring that precision surveillance and timely intervention transform MEN from a fatal prognosis into a chronically manageable condition.